 Biopharmaceutical company Jazz Pharmaceuticals plc NASDAQ: JAZZ announced Thursday that it has enrolled the first patient in its Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder. JZP150 is designed to address the underlying cause of PTSD and patients associated symptoms such as anxiety, insomnia and nightmares. 